Onyx Pharmaceuticals, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report by ICDResearch

VIEWS: 1 PAGES: 33

More Info
									Onyx Pharmaceuticals, Inc.

_________________________________________________________________________________



Onyx Pharmaceuticals, Inc.                                                    Financial Snapshot

                                                                              Operating Performance
Fast Facts
                                         2100 Powell Street, Emeryville,      The company reported revenue of US$324.51 million
Headquarters Address
                                         94608,United States of America       during the fiscal year 2010 (2010). The company's
                                                                              revenue grew at a CAGR of 82.08% during 2006–
Telephone                                + 12154889300
                                                                              2010, with an annual growth of 29.09% over 2009. In
                                                                              2010, the company recorded an operating margin of -
Fax                                      + 12154889301                        21.05%, as against 8.04% in 2009.

Website                                  www.onyx-pharm.com
                                                                              Revenue and Margins
Ticker Symbol, Stock Exchange            ONXX, NASDAQ

Number of Employees                      271

Fiscal Year End                          December

Revenue (in US$ million)                 324.51




SWOT Analysis

Strengths                                Weaknesses
                                         Dependence on the Agreement with
Focused Research and Development
                                         Bayer
                                         Dependence on Third Party
Strong Financial Performance
                                         Manufacturers

Strong Intellectual Property Portfolio

Opportunities                            Threats

Approval of Nexavar in Japan             Emergence of Biogenerics

Growth in the Prevalence of Cancer       Product Liability Claims

                                         Tightening of the FDA’s Regulatory
Product Pipeline
                                         Oversight
Rising Healthcare Expenditure in the
US




___________________________________________________________________________________________

Onyx Pharmaceuticals, Inc. - SWOT Profile                                                                          Page 1
Onyx Pharmaceuticals, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
2     Analysis of Key Performance Indicators ............................................................................................... 7
    2.1       Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
    2.2       Key Financial Performance Indicators .................................................................................................................10
      2.2.1       Revenue and Operating Profit .........................................................................................................................10
      2.2.2       Asset, Liabilities and Capex .............................................................................................................................11
      2.2.3       Solvency ..........................................................................................................................................................12
    2.3       Key Competitors ...................................................................................................................................................13
3     Mergers & Acquisitions and Partnerships ........................................................................................... 14
    3.1       M&A and Partnerships Strategy ...........................................................................................................................14
4     Recent Developments ........................................................................................................................... 16
5     SWOT Analysis ...................................................................................................................................... 18
    5.1       SWOT Analysis - Overview ..................................................................................................................................18
    5.2       Strengths ..............................................................................................................................................................18
    5.3       Weaknesses .........................................................................................................................................................18
    5.4       Opportunities ........................................................................................................................................................19
    5.5       Threats .................................................................................................................................................................19
6     Company Statement .............................................................................................................................. 21
7     History .................................................................................................................................................... 24
8     Key Employees ...................................................................................................................................... 26
9     Key Employee Biographies................................................................................................................... 27
10    Locations and Subsidiaries .................................................................................................................. 28
    10.1      Head Office ..........................................................................................................................................................28
    10.2      Other Locations and Subsidiaries ........................................................................................................................28
11    Appendix ................................................................................................................................................ 29
    11.1      Methodology .........................................................................................................................................................29
    11.2      Ratio Definitions ...................................................................................................................................................29
    11.3      Disclaimer.............................................................................................................................................................33




___________________________________________________________________________________________

Onyx Pharmaceuticals, Inc. - SWOT Profile                                                                                                                                   Page 2
Onyx Pharmaceuticals, Inc.

__________________________________________________________________________________________



List of Tables

Table 1: Major Products and Services....................................................................................................................................6
Table 2: Key Ratios - Annual ..................................................................................................................................................7
Table 3: Key Ratios - Interim ..................................................................................................................................................9
Table 4: Key Capital Market Indicators ..................................................................................................................................9
Table 5: History.....................................................................................................................................................................24
Table 6: Key Employees .......................................................................................................................................................26
Table 7: Key Employee Biographies ....................................................................................................................................27
Table 8: Subsidiaries ............................................................................................................................................................28




___________________________________________________________________________________________

Onyx Pharmaceuticals, Inc. - SWOT Profile                                                                                                                                  Page 3
Onyx Pharmaceuticals, Inc.

__________________________________________________________________________________________


List of Figures

Figure 1: Revenue and Operating Profit ............................................
								
To top